T1	AdverseReaction 52 62	Hemorrhage
T2	AdverseReaction 101 111	Infections
T3	AdverseReaction 193 203	Cytopenias
T4	AdverseReaction 257 276	Atrial Fibrillation
T5	AdverseReaction 335 362	Second Primary Malignancies
T6	AdverseReaction 420 432	skin cancers
T7	AdverseReaction 444 454	carcinomas
T8	AdverseReaction 471 491	Tumor Lysis Syndrome
T9	AdverseReaction 493 496	TLS
T10	AdverseReaction 573 594	Embryo-Fetal Toxicity
T11	AdverseReaction 606 616	fetal harm
T12	Factor 596 599	Can
T13	AdverseReaction 759 774	bleeding events
T14	AdverseReaction 843 858	bleeding events
T15	Severity 825 832	Grade 3
T17	AdverseReaction 860 877	subdural hematoma
T18	AdverseReaction 879 904	gastrointestinal bleeding
T19	AdverseReaction 906 915	hematuria
T20	AdverseReaction 920 946	post procedural hemorrhage
T21	AdverseReaction 987 995	Bleeding
T22	AdverseReaction 1027 1035	bruising
T23	AdverseReaction 1040 1049	petechiae
T24	Factor 1200 1203	may
T25	AdverseReaction 1225 1235	hemorrhage
T26	AdverseReaction 1521 1526	Fatal
T27	AdverseReaction 1541 1551	infections
T28	AdverseReaction 1609 1619	infections
T29	Severity 1590 1597	Grade 3
T31	AdverseReaction 1701 1743	progressive multifocal leukoencephalopathy
T32	AdverseReaction 1745 1748	PML
T33	AdverseReaction 1924 1934	cytopenias
T34	Severity 1911 1918	Grade 3
T35	Severity 1911 1916;1922 1923	Grade 4
T37	AdverseReaction 1945 1956	neutropenia
T38	AdverseReaction 1977 1993	thrombocytopenia
T39	AdverseReaction 2017 2023	anemia
T40	AdverseReaction 2165 2184	Atrial fibrillation
T41	AdverseReaction 2189 2203	atrial flutter
T42	AdverseReaction 2788 2800	malignancies
T43	AdverseReaction 2829 2848	non-skin carcinomas
T44	AdverseReaction 2964 2988	non-melanoma skin cancer
T45	AdverseReaction 3047 3067	Tumor lysis syndrome
T46	Animal 3300 3307	animals
T47	AdverseReaction 3329 3339	fetal harm
T48	AdverseReaction 3396 3409	malformations
T49	Animal 3413 3417	rats
T50	AdverseReaction 3613 3634	Reduced fetal weights
T51	AdverseReaction 370 382	malignancies
T52	AdverseReaction 753 758	Fatal
T16	AdverseReaction 2934 2959	second primary malignancy
T36	Severity 1531 1540	non-fatal
E1	AdverseReaction:T1
E2	AdverseReaction:T2
E3	AdverseReaction:T3
E4	AdverseReaction:T4
E5	AdverseReaction:T5
E6	AdverseReaction:T6
E7	AdverseReaction:T7
E8	AdverseReaction:T8
E9	AdverseReaction:T9
E10	AdverseReaction:T10
E11	AdverseReaction:T11 Hypothetical:E12
E12	Factor:T12
E13	AdverseReaction:T13
E14	AdverseReaction:T14 Effect:E15
E15	Severity:T15
E18	AdverseReaction:T17 Effect:E15
E19	AdverseReaction:T18 Effect:E15
E20	AdverseReaction:T19 Effect:E15
E21	AdverseReaction:T20 Effect:E15
E22	AdverseReaction:T21
E23	AdverseReaction:T22
E24	AdverseReaction:T23
E25	Factor:T24
E26	AdverseReaction:T25 Hypothetical:E25
E27	AdverseReaction:T26
E28	AdverseReaction:T27 Effect:E30
E29	AdverseReaction:T28 Effect:E32
E32	Severity:T29
E34	AdverseReaction:T31
E35	AdverseReaction:T32
E36	AdverseReaction:T33 Effect:E39
E38	AdverseReaction:T33 Effect:E40
E39	Severity:T34
E40	Severity:T35
E42	AdverseReaction:T37 Effect:E40 Effect2:E39
E43	AdverseReaction:T38 Effect:E40 Effect2:E39
E44	AdverseReaction:T39 Effect:E40 Effect2:E39
E45	AdverseReaction:T40
E46	AdverseReaction:T41
E47	AdverseReaction:T42
E48	AdverseReaction:T43
E49	AdverseReaction:T44
E50	AdverseReaction:T45
E51	Animal:T46
E52	AdverseReaction:T47 Hypothetical:E51
E53	AdverseReaction:T48 Hypothetical:E54
E54	Animal:T49
E55	AdverseReaction:T50
E56	AdverseReaction:T51
E57	AdverseReaction:T52
E16	AdverseReaction:T16
E30	Severity:T36
A1	CUI E1 C0019080
A2	UMLS-Preferred-Name E1 Hemorrhage
A3	MEDDRA-PT E1 Haemorrhage
A4	MEDDRA-PT-ID E1 10055798
A5	LLT E1 Hemorrhage
A6	LLT-ID E1 10019524
A7	CUI E2 C3714514
A8	UMLS-Preferred-Name E2 Infection
A9	MEDDRA-PT E2 Infection
A10	MEDDRA-PT-ID E2 10021789
A11	CUI E3 C0010828
A12	UMLS-Preferred-Name E3 Cytopenia
A13	MEDDRA-PT E3 Cytopenia
A14	MEDDRA-PT-ID E3 10066274
A15	CUI E4 C0004238
A16	UMLS-Preferred-Name E4 Atrial Fibrillation
A17	MEDDRA-PT E4 Atrial fibrillation
A18	MEDDRA-PT-ID E4 10003658
A19	CUI E5 C0751623
A20	UMLS-Preferred-Name E5 Second Primary Cancers
A21	MEDDRA-PT E5 Second primary malignancy
A22	MEDDRA-PT-ID E5 10039801
A23	CUI E6 C0007114
A24	UMLS-Preferred-Name E6 Malignant neoplasm of skin
A25	MEDDRA-PT E6 Skin cancer
A26	MEDDRA-PT-ID E6 10040808
A27	CUI E7 C0007097
A28	UMLS-Preferred-Name E7 Carcinoma
A29	MEDDRA-PT E7 Neoplasm malignant
A30	MEDDRA-PT-ID E7 10028997
A31	LLT E7 Carcinoma
A32	LLT-ID E7 10007284
A33	CUI E8 C0041364
A34	UMLS-Preferred-Name E8 Tumor Lysis Syndrome
A35	MEDDRA-PT E8 Tumour lysis syndrome
A36	MEDDRA-PT-ID E8 10045170
A37	LLT E8 Tumor lysis syndrome
A38	LLT-ID E8 10045152
A39	CUI E9 C0041364
A40	UMLS-Preferred-Name E9 Tumor Lysis Syndrome
A41	MEDDRA-PT E9 Tumour lysis syndrome
A42	MEDDRA-PT-ID E9 10045170
A43	LLT E9 Tumor lysis syndrome
A44	LLT-ID E9 10045152
A45	CUI E10 C0270009
A46	UMLS-Preferred-Name E10 Fetal or neonatal effect of toxic substance transmitted via placenta and/or breast milk
A47	MEDDRA-PT E10 Maternal drugs affecting foetus
A48	MEDDRA-PT-ID E10 10026923
A49	LLT E10 Drug toxicity NEC affecting foetus
A50	LLT-ID E10 10013750
A51	CUI E11 C0854268
A52	UMLS-Preferred-Name E11 Foetal damage
A53	MEDDRA-PT E11 Foetal damage
A54	MEDDRA-PT-ID E11 10016852
A55	LLT E11 Fetal damage
A56	LLT-ID E11 10054743
A57	CUI E13 C0019080
A58	UMLS-Preferred-Name E13 Hemorrhage
A59	MEDDRA-PT E13 Haemorrhage
A60	MEDDRA-PT-ID E13 10055798
A61	LLT E13 Bleeding
A62	LLT-ID E13 10005103
A63	CUI E14 C0019080
A64	UMLS-Preferred-Name E14 Hemorrhage
A65	MEDDRA-PT E14 Haemorrhage
A66	MEDDRA-PT-ID E14 10055798
A67	LLT E14 Bleeding
A68	LLT-ID E14 10005103
A69	CUI E18 C0018946
A70	UMLS-Preferred-Name E18 Hematoma, Subdural
A71	MEDDRA-PT E18 Subdural haematoma
A72	MEDDRA-PT-ID E18 10042361
A73	LLT E18 Subdural hematoma
A74	LLT-ID E18 10042380
A75	CUI E19 C0017181
A76	UMLS-Preferred-Name E19 Gastrointestinal Hemorrhage
A77	MEDDRA-PT E19 Gastrointestinal haemorrhage
A78	MEDDRA-PT-ID E19 10017955
A79	LLT E19 Gastrointestinal bleeding
A80	LLT-ID E19 10017936
A81	CUI E20 C0018965
A82	UMLS-Preferred-Name E20 Hematuria
A83	MEDDRA-PT E20 Haematuria
A84	MEDDRA-PT-ID E20 10018867
A85	LLT E20 Hematuria
A86	LLT-ID E20 10019450
A87	CUI E21 C0919874
A88	UMLS-Preferred-Name E21 Post procedural hemorrhage
A89	MEDDRA-PT E21 Post procedural haemorrhage
A90	MEDDRA-PT-ID E21 10051077
A91	LLT E21 Post procedural hemorrhage
A92	LLT-ID E21 10055320
A93	CUI E22 C0019080
A94	UMLS-Preferred-Name E22 Hemorrhage
A95	MEDDRA-PT E22 Haemorrhage
A96	MEDDRA-PT-ID E22 10055798
A97	LLT E22 Bleeding
A98	LLT-ID E22 10005103
A99	CUI E23 C0009938
A100	UMLS-Preferred-Name E23 Contusions
A101	MEDDRA-PT E23 Contusion
A102	MEDDRA-PT-ID E23 10050584
A103	LLT E23 Bruising
A104	LLT-ID E23 10006504
A105	CUI E24 C0031256
A106	UMLS-Preferred-Name E24 Petechiae
A107	MEDDRA-PT E24 Petechiae
A108	MEDDRA-PT-ID E24 10034754
A109	CUI E26 C0019080
A110	UMLS-Preferred-Name E26 Hemorrhage
A111	MEDDRA-PT E26 Haemorrhage
A112	MEDDRA-PT-ID E26 10055798
A113	LLT E26 Hemorrhage
A114	LLT-ID E26 10019524
A115	CUI E27 C1306577
A116	UMLS-Preferred-Name E27 Death (finding)
A117	MEDDRA-PT E27 Death
A118	MEDDRA-PT-ID E27 10011906
A119	CUI E28 C3714514
A120	UMLS-Preferred-Name E28 Infection
A121	MEDDRA-PT E28 Infection
A122	MEDDRA-PT-ID E28 10021789
A123	CUI E29 C3714514
A124	UMLS-Preferred-Name E29 Infection
A125	MEDDRA-PT E29 Infection
A126	MEDDRA-PT-ID E29 10021789
A127	CUI E34 C0023524
A128	UMLS-Preferred-Name E34 Leukoencephalopathy, Progressive Multifocal
A129	MEDDRA-PT E34 Progressive multifocal leukoencephalopathy
A130	MEDDRA-PT-ID E34 10036807
A131	CUI E35 C0023524
A132	UMLS-Preferred-Name E35 Leukoencephalopathy, Progressive Multifocal
A133	MEDDRA-PT E35 Progressive multifocal leukoencephalopathy
A134	MEDDRA-PT-ID E35 10036807
A135	CUI E36 C0010828
A136	UMLS-Preferred-Name E36 Cytopenia
A137	MEDDRA-PT E36 Cytopenia
A138	MEDDRA-PT-ID E36 10066274
A139	CUI E42 C0027947
A140	UMLS-Preferred-Name E42 Neutropenia
A141	MEDDRA-PT E42 Neutropenia
A142	MEDDRA-PT-ID E42 10029354
A143	CUI E43 C0040034
A144	UMLS-Preferred-Name E43 Thrombocytopenia
A145	MEDDRA-PT E43 Thrombocytopenia
A146	MEDDRA-PT-ID E43 10043554
A147	CUI E44 C0002871
A148	UMLS-Preferred-Name E44 Anemia
A149	MEDDRA-PT E44 Anaemia
A150	MEDDRA-PT-ID E44 10002034
A151	LLT E44 Anemia
A152	LLT-ID E44 10002272
A153	CUI E45 C0004238
A154	UMLS-Preferred-Name E45 Atrial Fibrillation
A155	MEDDRA-PT E45 Atrial fibrillation
A156	MEDDRA-PT-ID E45 10003658
A157	CUI E46 C0004239
A158	UMLS-Preferred-Name E46 Atrial Flutter
A159	MEDDRA-PT E46 Atrial flutter
A160	MEDDRA-PT-ID E46 10003662
A161	CUI E47 C0006826
A162	UMLS-Preferred-Name E47 Malignant Neoplasms
A163	MEDDRA-PT E47 Neoplasm malignant
A164	MEDDRA-PT-ID E47 10028997
A165	CUI E48 C0007097
A166	UMLS-Preferred-Name E48 Carcinoma
A167	MEDDRA-PT E48 Neoplasm malignant
A168	MEDDRA-PT-ID E48 10028997
A169	LLT E48 Carcinoma
A170	LLT-ID E48 10007284
A171	CUI E49 C0699893
A172	UMLS-Preferred-Name E49 Skin carcinoma
A173	MEDDRA-PT E49 Skin cancer
A174	MEDDRA-PT-ID E49 10040808
A175	LLT E49 Cancer of skin (excl melanoma)
A176	LLT-ID E49 10007116
A177	CUI E50 C0041364
A178	UMLS-Preferred-Name E50 Tumor Lysis Syndrome
A179	MEDDRA-PT E50 Tumour lysis syndrome
A180	MEDDRA-PT-ID E50 10045170
A181	LLT E50 Tumor lysis syndrome
A182	LLT-ID E50 10045152
A183	CUI E52 C0854268
A184	UMLS-Preferred-Name E52 Foetal damage
A185	MEDDRA-PT E52 Foetal damage
A186	MEDDRA-PT-ID E52 10016852
A187	LLT E52 Fetal damage
A188	LLT-ID E52 10054743
A189	CUI E53 C0000768
A190	UMLS-Preferred-Name E53 Congenital Abnormality
A191	MEDDRA-PT E53 Foetal malformation
A192	MEDDRA-PT-ID E53 10060919
A193	LLT E53 Fetal malformation
A194	LLT-ID E53 10060920
A195	CUI E55 C0015934
A196	UMLS-Preferred-Name E55 Fetal Growth Retardation
A197	MEDDRA-PT E55 Foetal growth restriction
A198	MEDDRA-PT-ID E55 10070531
A199	LLT E55 Fetal growth restriction
A200	LLT-ID E55 10070532
A201	CUI E56 C0006826
A202	UMLS-Preferred-Name E56 Malignant Neoplasms
A203	MEDDRA-PT E56 Neoplasm malignant
A204	MEDDRA-PT-ID E56 10028997
A205	CUI E57 C1306577
A206	UMLS-Preferred-Name E57 Death (finding)
A207	MEDDRA-PT E57 Death
A208	MEDDRA-PT-ID E57 10011906
A209	CUI E16 C0751623
A210	UMLS-Preferred-Name E16 Second Primary Cancers
A211	MEDDRA-PT E16 Second primary malignancy
A212	MEDDRA-PT-ID E16 10039801
